Parenteral diphosphonates for treating malignant hypercalcemia
- 15 October 1981
- Vol. 48 (8), 1922-1925
- https://doi.org/10.1002/1097-0142(19811015)48:8<1922::aid-cncr2820480833>3.0.co;2-2
Abstract
Two diphosphonates, EHDP (disodium etidronate, or ethanehydroxy-diphosphonate) and Cl2MDP (disodium clodronate, or dichloromethylene-diphosphonate) were injected in various doses in six patients with one or multiple episodes of malignant hypercalcemia. All patients responded well to the drugs after a delay period of two to seven days. The tolerance of the drugs was excellent. EHDP, and especially Cl2MDP, are promising agents for treating hypercalcemia and inhibiting bone resorption in malignant disorders.This publication has 8 references indexed in Scilit:
- Effects of Dichloromethylene Diphosphonate on Skeletal Mobilization of Calcium in Multiple MyelomaNew England Journal of Medicine, 1980
- DiphosphonatesCalcified Tissue International, 1979
- EFFECTS OF DISODIUM DICHLOROMETHYLENE DIPHOSPHONATE ON PAGET'S DISEASE OF BONEThe Lancet, 1979
- INHIBITION OF OSTEOLYTIC BONE LESIONS BY (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- TREATMENT OF PAGET'S DISEASE WITH (3-AMINO-1-HYDROXYPROPYLIDENE)-1, 1-BISPHOSPHONATE (A.P.D.)The Lancet, 1979
- Mechanisms of bone destruction in the development of skeletal metastasesNature, 1976
- The effect of two diphosphonates on the resorption of mouse calvariain vitroCalcified Tissue International, 1972
- The Effects of Diphosphonates, Polyphosphates, and Calcitonin on “Immobilisation Osteoporosis” in RatsEuropean Journal of Clinical Investigation, 1971